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In large European cities the tuberculosis (TB) epidemic is characteristically concentrated in 
vulnerable and under-served populations.[1] London has the highest number and annual incidence 
of TB in Europe and implemented routine surveillance on homelessness, drug and alcohol misuse 
and imprisonment among TB patients in 2009.[2] This paper describes the clinical, public health 
and epidemiological characteristics of TB cases and the public health impact of social risk factors 
including risk of infectiousness, onward transmission, poor treatment adherence and drug 
resistance. 
We analysed a cohort of adult London TB patients (2009-12) including clinical and laboratory 
surveillance information. This was improved by matching against the Find&Treat team’s database, 
who support TB patients across London with complex social needs.[3] Homelessness, 
imprisonment, drug and alcohol misuse were defined as per national guidance.[4] Multi-drug 
resistant (MDR) TB was defined as per WHO and poor treatment outcome was defined as not 
completing treatment within 12 months for rifampicin sensitive patients, or within 24 months for 
rifampicin resistant patients[5]. Recent migrants were defined as entering the UK less than two 
years before diagnosis. UN world region of birth was amended to a TB surveillance classification. 
Risk factors were identified for smear positive pulmonary disease; isoniazid and MDR (restricted to 
culture confirmed cases); non-adherence to treatment; and poor treatment outcomes (restricted to 
individuals notified 2009-11). Univariable analysis generated Odds Ratios (ORs), with 95% 
Confidence Intervals and (χ2) test for significance. Multivariable logistic regression was used to 
generate adjusted ORs, built using likelihood ratio tests (LRT). Variables were retained in the final 
model if they improved the fit of the model (p<0.05) or confounded a different exposure. Potential 
interactions were investigated based on a priori knowledge. Data were analysed using Stata 12. 
Of the cohort of 12,908 adult TB cases, 10% (1321) had one or more social risk factor: 
homelessness (550, 4%), imprisonment (349, 3%), drug (436, 3%) or alcohol misuse (581, 5%). 
Cases with social risk factors were more often male (79% vs. 55%, p<0.001) UK born (29% vs. 
12%, p<0.001) white (25% vs. 9%, p<0.001) or black Caribbean (7% vs. 3%, p<0.001). Multiple 
factors were common (393 patients, 30%, reported two or more). 
We stratified the multivariable analysis for infectious disease by drug use due to the interaction 
between drug use and homelessness (LRT p=0.0071). No further interactions were identified.  
Infectious disease  
Among 4,501 pulmonary patients with no history of drug use: 58% (134/231) of homeless patients 
were smear positive. Homelessness was independently associated with being sputum smear 
positive (aOR 1.8, 95% CI 1.4-2.4), as was being aged under 45. Those born in South Asia were 
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less likely to have infectious TB (than those born elsewhere). Among the 173 cases reporting drug 
misuse, no further characteristics were associated with infectiousness. 
Drug resistance  
Nineteen percent (73/393) of homeless patients had isoniazid resistant and 5% (20/393) had 
MDRTB. Homelessness was an independent risk factor for isoniazid (aOR 1.9, 95%CI1.4-2.6) and 
MDR disease (aOR 2.9, 95% CI1.6-5.2), while problem drug use was associated with isoniazid 
resistance. Being born in East Europe or East Asia, and a previous history of TB was also 
associated with drug resistance. Recent migrants were more likely to be MDR, while patients aged 
65 or more were less likely to have drug resistance. 
Non-adherence and not completing treatment  
Almost half of all homeless patients were non-adherent (258/550), and 72% (303/420) completed 
treatment. Homelessness was associated with non-adherence (aOR 10.2, 95% CI 7.9-13.2) and 
not completing treatment (aOR 2.6, 95% CI 2.0-3.3). The other social risk factors were also 
independently associated with non-adherence, as was young age (under 25 years), pulmonary 
disease, a previous history of TB and being born in Central and West Europe.   
Other characteristics associated with not completing treatment were being aged under 25 years or 
older than 54, male, born in East Europe, having pulmonary disease and being a recent migrant.  
The increased risk of infectious TB among patients with social risk factors may relate to lung 
damage from smoking tobacco and/or crack cocaine, or delayed diagnosis.[6,7]  Risk of drug 
resistance for those born in East Europe or East Asia reflects the burden of drug resistant TB in 
those areas. The increased risk of drug resistant TB among homeless people and drug users, after 
controlling for country of birth and previous treatment, suggests transmission of drug resistant 
disease in London, where homelessness is also a known risk factor for clustering.[8] 
All social risk factors were associated with non-adherence. Patients experiencing homelessness 
were most at risk (aOR 10.2, 95% CI 7.9-13.2). This increased with social complexity: 83% of 
patients with four factors were non-adherent compared to 16% with one risk factor.  
Homelessness was associated with not completing treatment. Males and those born in East 
Europe were also less likely to complete treatment, possibly due to under-reporting of social risk 
factors. Poor outcomes among recent migrants may reflect a preference to return to home 
countries for treatment, and among older patients the impact of co-morbidities.  
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TB patients with social risk factors have a disproportionate public health impact. Just 4% 
experienced homelessness but this was 16% of MDR and 36% of non-adherent patients. This 
supports UK guidance recommending assessing and supporting patient social risk factors, 
maintaining adequate staffing to support socially complex cases, and using cohort review as a 
quality assurance tool.[4,9] UK guidance for homeless people and drug-users also recommends 
targeted TB case finding using mobile digital chest radiology; integrated screening and treatment 
for latent TB infection, hepatitis C and HIV; and enhanced case management through diagnosis 
and treatment.[9]  
It has been recognised that TB control efforts in low incidence countries should focus in big urban 
centres.[10] The implementation of targeted approaches was reviewed in an international survey of 
TB elimination practices in low incidence European countries, and followed by a consensus 
statement of the ECDC TB in big cities working group. This detailed recommendations to improve 
early case finding, case holding and treatment completion, especially among vulnerable 
groups.[11,12] Despite the mostly low incidence, the economic cost of TB in the EU remains 
considerable (total costs of €536,890,315 accumulated in 2012).[13]  
Limitations to our study include that surveillance likely underestimates the prevalence of social risk 
factors. We increased by 24% the proportion known as homeless after matching to a specialist 
outreach service database (445 to 550). Patients missing information were assumed to not have 
that factor, which may have weakened associations identified. Other missing information reduced 
the study power to identify risk factors for infectiousness (sputum smear missing for 22% of 
pulmonary patients) and drug resistance (susceptibility unknown for 42% of patients). Individual 
HIV status was unknown: however co-infection estimates were low at approximately 4% of TB 
patients during this time period (personal communication, PHE National Infection Service January 
2016). 
Our study confirms that TB patients in London with social risk factors are more likely to be 
infectious, drug resistant, and not complete treatment and reveals homelessness as an 
independent risk factor for MDR disease. This convergence of clinical and social complexity 
presents an immense challenge and underlines the need for investment in specialist outreach 
services to tackle TB among vulnerable and medically under-served populations. We welcome the 
Collaborative Tuberculosis Strategy for England 2015 to 2020 which committed new investment to 
tackling TB in under-served populations.[14]   
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Table 1: Multivariable analysis of patient characteristics associated with infectiousness, drug resistance, non-adherence and poor outcomes 
Patient characteristics (n) 
Sputum smear positive* 
n=2179 
Isoniazid resistant** 
n=646 
Multi-drug resistant** 
n=127 
Non-adherent 
n=717 
Did not complete*** 
n=1207 
 N=12908 aOR (95% CI)# p-value aOR (95% CI) p-value aOR (95% CI) p-value aOR (95% CI) p-value aOR (95% CI) p-value 
Age 16-24  (2289) 1.2 (1.0-1.4) 0.059 1.0 (0.8-1.3) 0.877 2.0 (1.2-3.1) 0.004 1.5 (1.2-1.9) 0.001 1.2 (1.1-1.4) 0.001 
  25-34  (4200) Ref  Ref  Ref  Ref  Ref  
  35-44  (2512) 0.8 (0.7-1.0) 0.051 1.1 (0.8-1.4) 0.598 0.9 (0.5-1.6) 0.702 0.8 (0.6-1.1) 0.183 0.9 (0.8-1.1) 0.408 
  45-54  (1638) 0.7 (0.6-0.9) 0.004 1.2 (0.9-1.5) 0.273 1.1 (0.6-2.1) 0.772 0.8 (0.6-1.1) 0.216 1.2 (1.0-1.5) 0.074 
  55-64  (980) 0.7 (0.6-0.9) 0.012 1.0 (0.7-1.5) 0.957 0.6 (0.21.8) 0.383 0.7 (0.5-1.1) 0.158 1.4 (1.1-1.7) 0.013 
  65+     (1289) 0.6 (0.5-0.7) <0.001 0.6 (0.4-0.8) 0.005 0.1 (0.01-0.8) 0.030 0.5 (0.3-0.7) 0.001 2.6 (2.2-3.2) <0.001 
Male  (7470)                 1.3 (1.1-1.4) 0.0006 
World 
region 
of 
birth† 
Central Europe  (317) 1.9 (1.4-2.5)# <0.001 0.8 (0.5-1.4) 0.435 1.7 (0.8-3.9) 0.194 2.0 (1.3-3.1) 0.002 1.3 (0.9-1.9) 0.100 
East Asia  (147) 1.8 (1.2-2.7)# 0.008 1.9 (1.0-3.4) 0.045 3.7 (1.5-9.1) 0.004 1.6 (0.8-3.3) 0.182 1.4 (0.9-2.3) 0.154 
East Europe  (84) 2.1 (1.3-3.6)# 0.005 4.0 (2.2-7.2) <0.001 7.6 (3.4-17.0) <0.001 1.9 (0.9-4.1) 0.116 1.9 (1.1-3.3) 0.026 
East Mediterranean  (97) 1.2 (0.6-2.5)# 0.570 - - - - 0.3 (0.1-1.4) 0.128 1.5 (0.8-2.9) 0.253 
  North Africa  (112) 1.3 (0.7-2.4)# 0.450 - - - - 0.7 (0.3-1.9) 0.504 0.5 (0.2-1.1) 0.072 
  North America & Oceania  (26) 0.9 (0.3-2.7)# 0.811 - - - - 0.9 (0.1-7.0) 0.926 1.1 (0.3-3.6) 0.931 
  South Asia  (5888) Ref   Ref   Ref   Ref   Ref  
  South East Asia  (393) 1.4 (1.0-1.9)# 0.032 1.1 (0.7-1.8) 0.738 1.0 (0.3-2.7) 0.93 1.6 (1.0-2.6) 0.077 1.1 (0.8-1.5) 0.690 
  
South, Central America & the 
Caribbean  (297) 
2.3 (1.7-3.2)# <0.001 0.8 (0.4-1.5) 0.523 - - 1.6 (0.9-2.8) 0.081 0.9 (0.6-1.4) 0.651 
  Sub-Saharan Africa  (3023) 1.2 (1.1-1.4)# 0.004 0.8 (0.6-1.0) 0.068 0.6 (0.4-1.0) 0.045 1.0 (0.8-1.2) 0.74 0.7 (0.6-0.9) <0.001 
  West Europe‡  (1948) 1.9 (1.7-2.3)# <0.001 1.1 (0.9-1.4) 0.318 0.6 (0.3-1.1) 0.073 1.3 (1.0-1.7) 0.046 1.1 (0.9-1.3) 0.248 
Recent migrant (<2 years)*  (1981)         1.7 (1.1-2.8) 0.023     1.5 (1.3-1.8) <0.0001 
Previous TB   (772)     1.5 (1.1-2.2) 0.026 4.4 (2.6-7.5) <0.001 1.7 (1.2-2.3) 0.0029     
Pulmonary   (6184) - -         1.7 (1.4-2.0) <0.0001 1.2 (1.1-1.4) 0.0013  
Social risk 
factors 
Problem drug use  (436) - - 2.4 (1.7-3.3) <0.000
1 
    3.0 (2.2-4.1) <0.0001     
Alcohol  (581) 1.4 (1.1-1.8)# 0.0140       2.9 (2.2-3.9) <0.0001     
Prison  (349)           2.3 (1.6-3.2) <0.0001     
  Homelessness  (550) 1.8 (1.4-2.4)# <0.0001 1.9 (1.4-2.6) 0.0003 2.9 (1.6-5.2) <0.001 10.2 (7.9-13.2) <0.0001 2.6 (2.0-3.3) <0.0001 
*among pulmonary cases only 
**among culture confirmed cases only 
***did not complete an un-interrupted course of treatment within 12 months if rifampicin sensitive, and 24 months if rifampicin resistant 
#among patients without problem drug use. Among patients with problem drug use, no further characteristics were associated with sputum smear positive disease 
† world region of birth is based on UK ETS classification, based on country of birth. Central  
‡76% of patients from West Europe were born in the UK 
 
